- Bristol-Myers Squibb (NYSE: BMY) is a leading global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases, reporting full-year revenues of $48.2 billion in 2025.
- In 2025, the company achieved a 1% increase in fourth-quarter revenues to $12.5 billion, driven by a 16% growth in its Growth Portfolio, which includes key products like Reblozyl and Opdualag.
- Bristol-Myers Squibb has established strong partnerships and customer relationships in the healthcare sector, with significant contributions from its oncology and cardiovascular product lines, which are pivotal in addressing critical patient needs.
- Sales teams should focus on Bristol-Myers Squibb as they prepare for a 'data-rich' 2026, with multiple pivotal product readouts expected, indicating a strong pipeline that could address significant market gaps in oncology and other therapeutic areas.
Bristol-Myers Squibb's workforce is organized into 19 departments, with Operations leading at 2,978 employees, followed closely by Community and Social Services with 2,088. The Executive department also plays a significant role, comprising 2,049 personnel. This distribution indicates a strong emphasis on operational and community engagement functions, while also maintaining a balanced presence across various support and technical departments such as Information Technology and Engineering.
The company's workforce is distributed across 945 locations, with a significant concentration in New York, NY, housing 3,323 employees, followed by Summit, NJ, at 784 and Princeton, NJ, at 576. The presence of a large 'Other' category, accounting for 9,064 employees, suggests a widespread geographic distribution that may include remote or smaller operational sites. This distribution reflects a strategic approach to leveraging diverse locations to support the company's extensive operations.
